GSK shares were up 0.3% to 1,733.7p in early morning trading on Tuesday, following the company’s acquisition of US clinical-stage biopharmaceutical company, Affinivax. GSK is set to acquire 100% of outstanding Affinivax shares, and confirmed that it would pay $2.1 billion immediately, and up to $1.2 billion in potential paediatric developmental milestones in separate payments […]

The post GSK acquires biopharma group Affinivax for $3.3bn appeared first on UK Investor Magazine.